These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 25596730)

  • 1. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
    Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
    Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
    Chen R; Keating MJ; Gandhi V; Plunkett W
    Blood; 2005 Oct; 106(7):2513-9. PubMed ID: 15972445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
    Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
    Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
    Mahoney E; Lucas DM; Gupta SV; Wagner AJ; Herman SE; Smith LL; Yeh YY; Andritsos L; Jones JA; Flynn JM; Blum KA; Zhang X; Lehman A; Kong H; Gurcan M; Grever MR; Johnson AJ; Byrd JC
    Blood; 2012 Aug; 120(6):1262-73. PubMed ID: 22740450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
    Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
    Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
    Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
    Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
    Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
    Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling.
    Yu Z; Du J; Zhao Y; Gao Y; Li Y; Zhao K; Lu N
    Cancer Lett; 2021 Feb; 498():31-41. PubMed ID: 33129955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
    Dow EC; Liu H; Rice AP
    J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
    Liu X; Shi S; Lam F; Pepper C; Fischer PM; Wang S
    Int J Cancer; 2012 Mar; 130(5):1216-26. PubMed ID: 21484792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
    Incles CM; Schultes CM; Kelland LR; Neidle S
    Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
    Hou T; Ray S; Brasier AR
    J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
    Mahoney E; Byrd JC; Johnson AJ
    Autophagy; 2013 Mar; 9(3):434-5. PubMed ID: 23422081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.
    Schmerwitz UK; Sass G; Khandoga AG; Joore J; Mayer BA; Berberich N; Totzke F; Krombach F; Tiegs G; Zahler S; Vollmar AM; Fürst R
    Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):280-8. PubMed ID: 21088252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
    Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
    Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
    Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR
    Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma.
    Tong Z; Chatterjee D; Deng D; Veeranki O; Mejia A; Ajani JA; Hofstetter W; Lin S; Guha S; Kopetz S; Krishnan S; Maru D
    Oncotarget; 2017 Apr; 8(17):28696-28710. PubMed ID: 28404924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
    Bates DJ; Salerni BL; Lowrey CH; Eastman A
    Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.